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Percutaneous transluminal angioplasty was used to treat 
101 patients with saphenous vein bypass graft stenosis at a 
mean of 50.1 months (range 2 to 196) after coronary artery 
bypass surgery. The patients presented between March 
1981 and April 1987. A total of 107 saphenous vein grafts 
were dilated at 117 sites. 
The primary success rate was 91.8%. The incidence of 
cardiac complications was 7.1%. There were no cardiac 
complications in 53 patients with grafts implanted ~36 
months before angioplasty (Group 1). The 48 patients with 
grafts implanted for >36 months (Group 2) had a 12.5% 
incidence rate of myocardial infarction, a 4% incidence 
rate of emergent bypass surgery and a 4% incidence rate of 
death for an overall cardiac complication rate of 14.9% 
(p <: 0.01). 
Follow-up was obtained at a mean of 16.8 + 13.9 
months (range 1 to 54) in 87 patients (97% of successful 
cases). Repeat coronary angiography was performed in 49 
patients and revealed restenosis in 30 patients (61.2%), 
with no difference in recurrence rates for proximal, mid or 
distal graft sites. Clinical recurrence (defined as recurrence 
of symptoms, myocardial infarction, repeat angioplasty, 
surgery or death) was 33.1% for Group 1 patients and 
64.1% for Group 2 patients (p < 0.01). 
The complication and recurrence rates of saphenous 
vein graft angiography are significantly higher when per- 
formed for late (>36 months) vein graft failure. All thera- 
peutic options should he carefully examined before pro- 
ceeding with angioplasty for saphenous vein graft stenosis 
in this type of patient. 
(,I Am Co11 Cardiol 1989;14:1645-SO) 
The performance of the first saphenous vein coronary artery 
graft by Favaloro (1) in 1967 dramatically altered the treat- 
ment of coronary artery disease. Serial angiographic studies 
have revealed, however, that graft patency at 1 year is only 
70% to 85% (24). and that there is an annual graft attrition 
rate of 1% to 3% per year until years 5 to 7 when vein graft 
occlusion increases because of late atherosclerosis (2-7). 
The average time to recurrence of angina1 symptoms after 
operation is approximately 2.5 years for all patients and as 
little as I7 months for those presenting with graft failure (8). 
Initially, the options for therapy were either medical therapy 
with its lower incidence of symptom relief or repeat coro- 
nary artery bypass grafting with its attendant increased risks 
(8-1 I ). 
The introduction of percutaneous transluminal coronary 
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Study patients. A retrospective review was undertaken 
for all cases of percutaneous transluminal angioplasty of 
saphenous vein grafts performed at the Cleveland Clinic 
Foundation during the 73 month period between March 1981 
and April 1987. Clinical information at the time of initial 
presentation and data obtained at the time of the procedure 
were recorded on standard forms by a physician. Angio- 
graphic measurement of vessel stenosis was performed by 
using mechanical calipers and reported as the average of two 
orthogonal projections. 
Angioplasty of a saphenous vein graft was performed in 
81989 h) the American College of Cardiology 073s-1097’8’)/$3.50 
angioplasty by Gruentzig et al. (12) in 1977 presented cardi- 
ologists with another option for therapy in the patient with 
recurrent angina after coronary artery surgery. The use of 
this technique in patients with prior coronary artery bypass 
grafting has been described in several recent reports (13-19). 
This report describes the results of angioplasty of coronary 
artery bypass grafts at the Cleveland Clinic Foundation over 
a 6 year period from 1981 to 1987. 
Methods 
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101 patients. Clinical follow-up data were obtained for 87 
(96.7%) of 90 successful elective procedures, with three 
patients lost to follow-up. Charts of all 87 patients were 
reviewed. Telephone contact was made with patients, fam- 
ilies or referring physicians. They were questioned as to 
recurrence of symptoms or hospitalizations for angina, con- 
gestive heart failure or myocardial infarction. The families or 
physicians, or both, of deceased patients were interviewed 
in an effort to ascertain cause of death. Autopsy results were 
obtained when available. 
Most of the repeat catheterization procedures were per- 
formed in our laboratory. Results of outside studies were 
obtained for review. All patients were assessed at a mini- 
mum of 6 months after angioplasty unless clinical conditions 
warranted earlier evaluation. 
Angioplasty technique. In all cases, percutaneous trans- 
luminal angioplasty was performed by means of the femoral 
approach, with a technique similar to that described else- 
where (20,21). All patients received aspirin or aspirin and 
dipyridamole 12 to 24 h before the procedure. Calcium 
channel blockers have also routinely been given since 1983. 
Nitrates and beta-adrenergic blockers were continued if 
clinically indicated. 
Definitions. Diabetes mellitus was defined as elevated 
serum glucose levels requiring pharmacologic treatment. 
Elevated cholesterol was defined as a total serum cholesterol 
>240 mg/dl. Smoking history was considered positive if 
there was a > 10 pack-year history. 
Complications were dejined according to the National 
Heart, Lung, and Blood Institute definitions (22) as follows. 
Myocardial infarction was diagnosed by the presence of two 
of the three following criteria: prolonged angina, electrocar- 
diographic criteria for infarction using the Minnesota code 
(23) and elevation of creatine kinase or creatine kinase MB 
isoenzyme to more than three times normal (upper limits of 
normal 180 W/liter and 4%, respectively). Emergency sur- 
gery was defined as the need for an urgent operation as a 
direct result of complications from the procedure. A central 
nervous system event was recorded if a transient or persist- 
ent neurologic event occurred. Death was considered a 
complication if it occurred before hospital discharge. Symp- 
tomatic status was based upon the Canadian Cardiovascular 
Society functional classification (24). 
Statistical analysis. Tests for mean differences were per- 
formed with the two-tailed Student’s t test. Two way tables 
were developed for categoric variables. Chi-square or Fish- 
er’s exact test was used depending on expected cell frequen- 
cies. 
Results 
Patient profiles (Table 1). Percutaneous transluminal an- 
gioplasty of saphenous vein bypass grafts was attempted in 
101 patients. Ninety-eight procedures were elective and 
Table 1. Clinical Profile of 101 Patients 
Mean age (yr) 
Female (%) 
Time after surgery (months) 
Mean 
Range (months) 
Diabetes mellitus (%) 
Hypertension (%) 
Hypercholesterolemia (%) 
History of tobacco use (%) 
Canadian Heart Association functional class (%) 
I 
II 
I11 
IV 
Elective procedures (no.) 
Total vein grafts (no.) 
Total sites dilated (no.) 
Single site (no.) 
Two sites (no.) 
59.9 
18.8 
50.2 k 49.1 
2 to 196 
13.9 
55.4 
26.3 
75.0 
5.0 
24.8 
42.6 
27.7 
98 
107 
117 
83 
17 
three were performed emergently for acute myocardial in- 
farction. The grafts dilated included 38 to the right coronary 
artery, 32 to the left circumflex artery and 37 to the left 
anterior descending artery. Of the 17 patients who had 
angioplasty at more than one site, 10 had dilation of a single 
site in two different grafts, 2 had dilation of a graft and a 
native coronary artery and 5 had dilation of two sites in a 
single graft. 
Patients undergoing native vessel angioplasty by means 
of a saphenous vein graft conduit but without bypass graft 
dilation were not included in this analysis. Patients under- 
going internal thoracic artery graft angioplasty were also not 
included. 
Initial procedure (Table 2). A successful procedure was 
defined as a stenosis reduction >20% with residual stenosis 
of 550% with no complications requiring coronary artery 
bypass surgery or resulting in death. This was achieved in 90 
(91.8%) of 98 elective procedures and 98 (90%) of 109 grafts. 
Dilations were successful in 47 (88.7%) of 53 proximal graft 
lesions, 24 (100%) of 24 lesions in the body of the graft and 
28 (93.3%) of 30 distal graft lesions (p = NS). 
Procedural complications. There were five patients in 
whom the lesion could not be dilated. Three of these were 
Table 2. Primary Results in 98 Cases of Elective Vein 
Graft Angioplasty 
Success (%) 
Failure (%) 
Medical therapy (%) 
Elective bypass surgery (%) 
Emergent bypass surgery (%) 
Death (%) 
91.8 (90) 
3.1 (3) 
1.0 (1) 
2.0 (2) 
2.0 (2) 
Values in parentheses indicate number of patients. 
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subsequently treated medically, one underwent elective by- 
pass surgery and one required emergent bypass surgery and 
sustained an inferior wall myocardial infarction. Major car- 
diac events (myocardial infarction, emergency surgery or 
death) occurred in seven patients (7.1%). One patient re- 
quired emergent bypass surgery and sustained an anterior 
infarction after dissection of a vein graft to the left anterior 
descending artery. Three patients had angiographically suc- 
cessful dilation of the vein graft, but sustained nontransmu- 
ral myocardial infarction; there was angiographic documen- 
tation of distal embolization in two of these patients. There 
were no episodes of acute occlusion of the grafts dilated in 
the study patients, 
There were two in-hospital deaths. One occurred in a 72 
year old man who presented 72 months after operation with 
recent progression of angina1 symptoms. He was found to 
have an occlusion of the vein graft to the left anterior 
descending artery at the proximal site. This was successfully 
opened, but subsequently thrombosed and could not be 
reopened. The patient had a cerebrovascular accident after 
the procedure, developed acute renal failure and died I 
month later. 
The second death occurred in a 72 year old man 187 
months after his bypass surgery. He presented with Cana- 
dian Heart Association functional class IV symptoms and 
was found to have a 79% stenosis at the distal anastomotic 
site of a vein graft to the left anterior descending artery; he 
was not considered a surgical candidate because of two prior 
coronary revascularization procedures. The patient had 
angiographic evidence of arterial embolism at the time of 
angioplasty. He died 1 week later. Postmortem examination 
revealed evidence of multiple embolic myocardial infarcts. 
Early versus late vein graft angioplasty (Table 3). The 
patients were classified into two groups based on the age of 
the graft. There were 53 patients (52.5%) who had surgery 
536 months before angioplasty was performed (Group 1). 
There were 48 patients (47.5%) who had surgery >36 months 
before angioplasty (Group 2). The groups were well matched 
for coronary risk factors, symptom and lesion location. 
Analysis showed no difference between the groups in terms 
of lesion configuration, number and duration of inflations 
and balloon to vein graft ratio during angioplasty. After the 
procedure. there was no difference in intimal dissection 
between the two groups (9.2% in Group 1 versus 14.9% in 
Group 2. p = NS). Residual stenosis, however, was signifi- 
cantly greater in the Group 2 patients (Fig. 1). 
All cardiac complicatioms occurred in the patients with 
late vein grqfi stenosis (Fig. 2). These patients had a 12.5% 
incidence rate of myocardial infarction, a 4% incidence of 
emergent bypass surgery, and a 4% mortality. 
Follow-up. Eighty-seven of the 90 patients with success- 
ful angioplasty were followed-up for an average of 16.8 ? 
13.9 months (range 1 to 54). Cardiac catheterization was 
performed in 49 patients (56.3%). An additional 17 patients 
Table 3. Clinical Profile Based on Graft Age in 101 Patients 
Group I Group 2 
P 
(~36 months) I >3h months) Value 
Patients (no.1 
Mean age (yr) 
Female (%) 
Time after surgery 
(months t SD) 
Diabetes mellitus (R) 
Hypertension t5?) 
Hypercholesterolemia (cl) 
History of smoking (%) 
Functional angina1 class (“0) 
I 
II 
III 
IV 
Vessel grafted 
Right coronary artery (%) 
Left anterior descending (%) 
Left circumflex artery ((r) 
Graft lesion dilated 
Proximal (%) 
Body (%) 
Distal (c/c) 
Patients with 
> I vessel PTCA (%) 
Repeat catheterization (R) 
53 
59.6 
22.6 (I?) 
II.0 2 9.4 
7.6 (4) 
54.1 (29) 
26.0 (13) 
73.2 (38) 
I.9 II) 
24.5 (13) 
45.3 (24) 
28.3 (IS) 
41.8 (23) 
32.1 (IX) 
25.4 (14) 
46.3 (25) 
22.2 (12) 
31.5 (17) 
II.3 (6) 
49.0 (26) 
4x NS 
60.2 NS 
14.6 (7) NS 
91.8 i 38.7 0.0001 
20.8 (IO) 0.05 
56.3 (27) NS 
26.7 (12) NS 
77.1 (37) NS 
x.3 (4) NS 
25.0 (I?) NS 
39.6 (19) NS 
27.1 (13) NS 
28.8 (15) NS 
36.5 (19) NS 
-34.6 (18) NS 
52.8 (28) NS 
22.6 (I?) NS 
24.6 (13) NS 
10.4 (5) NS 
41.9 (23) NS 
Values in parentheses indicate total number of patients. PTCA = percu- 
taneous transluminal coronary angioplasty. 
(19.5%) had a stress test performed at 16.1 2 3.4 months 
(mean 2 SD) after the procedure. The remaining 21 patients 
(24.2%) were followed up clinically. 
Recurrence was classijied angiographically as stenosis of 
>.50’% on repeat catheterization. If no repeat catheterization 
was performed, additional criteria for clinical recurrence 
were an abnormal stress test or recurrence of the patient’s 
initial symptoms. or both, with deterioration to Canadian 
Figure 1. Percent luminal stenosis before (PRE) (n = 101) and after 
(POST) (n = 48) vein graft angioplasty based on graft age. 
p=NS p<o.os 
0 
PRE POST 
536 MO.0 
>36 M0.m 
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Figure 2. Complication rate of vein graft angioplasty for Group 1 
(graft age ~36 months) (n = 53) compared with Group 2 (graft age 
>36 months) (n = 48). 
Heart functional class III or IV at any point during the 
follow-up period. If the patient died during the follow-up 
period and the death was either sudden or of known cardiac 
origin, the patient was also classified as having had a 
recurrence. Data were analyzed for the entire group and for 
a comparison of Groups 1 and 2 (Table 4). 
Graft restenosis. Angiographic recurrence was found in 
30 (61.2%) of 49 patients at the time of catheterization. An 
additional two patients had a positive stress test at 1 and 26 
months after angioplasty, respectively, but were treated 
medically. Nine additional patients were classified as having 
a recurrence on the basis of history. Five of these patients 
had either recurrence of symptoms, myocardial infarction or 
cardiac death within 6 months of the procedure. Angio- 
graphic or clinical recurrence, or both, for the entire group 
was observed in 41 patients (47.1%). 
Recurrence rates were evaluatedfor each site of stenosis. 
There was no significant difference in the rate of recurrence 
based on the graft site dilated. Angiographic or clinical 
recurrence, or both, occurred in 21 (50%) of 42 proximal 
lesions, 9 (45%) of 20 lesions of the body of the graft and 10 
(42%) of 24 distal lesions dilated. 
The recurrence rate for the Group I patients (early graft 
failure) was compared with that for the Group 2 patients 
Table 4. Follow-up Data Based on Graft Age in 87 Patients 
Group 1 Group 2 
(~36 months) (>36 months) p Value 
Patients (no.) 
Time of follow-up 
(months + SD) 
Functional class 1 or II and 
free from angiographic 
recurrence of late cardiac 
event (%) 
Angiographic recurrence (%) 
Myocardial infarction (%) 
Repeat bypass surgery (%) 
Repeat angioplasty (%) 
Death (%) 
48 39 NS 
19.1 2 14.5 14.0 k 12.7’ NS 
66.7 35.9 0.004 
42.3 82.6 CO.01 
12.1 28.2 0.06 
14.0 26.8 NS 
10.0 12.8 NS 
12.0 10.5 NS 
0” ou 
0 6 12 18 24 30 36 42 48 54 
MONTHS AFTER PTCA 
NUMSER<36MO. 46 36 30 26 21 15 10 7 2 1 
ATRISK >36MO. 41 26 16 15 11 7 6 3 2 1 
Figure 3. Percent survival without any cardiac event (myocardial 
infarction, repeat angioplasty, surgery, death or symptom recur- 
rence) for all 87 patients based on graft age (5 or >36 months). 
PTCA = percutaneous transluminal coronary angioplasty. 
(late graft failure). Forty-two percent of Group 1 patients 
had angiographic recurrence compared with 83% of Group 2 
patients (p = 0.01). Clinical recurrence, defined as a cardiac 
event (that is, myocardial infarction, repeat angioplasty or 
bypass surgery or death) or progression to Canadian Heart 
Association functional class III or IV, was 33.3% for Group 
1 and 64.1% for Group 2 (p < 0.01) (Fig. 3). 
Discussion 
Primary results and complications. These data suggest 
that although saphenous vein graft angioplasty can be per- 
formed with a good primary success rate (92% over the time 
of this study), there are a few caveats. The overall compli- 
cation rate was 7.1%, with a 5.9% incidence of myocardial 
infarction. Three of the six myocardial infarcts were the 
result of distal embolization of the atherosclerotic material at 
the time of angioplasty. These findings are in agreement with 
that reported by Douglas et al. (18), and are slightly higher 
than reported in other series (19,25). 
Graft age and primary results. The study cohort classi- 
fied into two groups based on the age of the vein graft. There 
is good evidence (2629) to support that in the absence of 
hyperlipidemia, it is unusual to find organized atheroscle- 
rotic plaques in grafts implanted <36 months. For this 
reason, the patients who had coronary artery surgery within 
the previous 36 months (Group 1) were compared with those 
who were >36 months from the time of their surgery (Group 
2). Most baseline characteristics of the groups were well 
matched. However, Group 2 had a significantly greater 
proportion of diabetic patients (20.8 versus 7.6% for Group 
1, p = 0.05). 
The complication rate was signijicantly higher in Group 
2. Additionally, even though the groups were matched for 
vessels bypassed and distribution of lesions among the 
proximal, distal and mid portion of the grafts, there was a 
significant difference in the residual stenosis after angio- 
plasty in the Group 2 patients. These findings may be due in 
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part to the different pathologic process involved in early 
compared with late graft failure (25-29). 
Recurrence. Recurrence rates were assessed on the basis 
of the angiographic findings. This method is likely to be 
unfavorably weighted with those patients who had recur- 
rence because they would more likely be symptomatic, thus 
leading to a repeat catheterization. For this reason, recur- 
rence was also assessed on the basis of clinical data. The 
angiographic recurrence rate was 61.2% for the 49 patients 
who had cardiac catheterization. The clinical recurrence rate 
was only slightly lower at 47.1% for the entire group. When 
the study cohort was divided on the basis of graft age, there 
was a significantly higher rate of angiographic and clinical 
recurrence with the older vein grafts. 
Factors influencing recurrence. The different restenosis 
rates in patients with early versus late vein graft stenosis 
might be explained by the different pathologic processes 
resulting in graft stenosis in these two groups (26-29). 
Unfortunately, a confounding factor that makes a firm con- 
clusion difficult is the higher incidence of diabetic patients in 
Group 2. This may have played a part in the increased 
restenosis rate in this group because five of the seven 
diabetic patients who were followed up had recurrent steno- 
sis. 
The overall rate of angiographic recurrence is signifi- 
cantly higher than that in any studies reported thus far 
(15,17,19,30-32) and is also higher than the 30% recurrence 
rate reported earlier from this institution (33) in 43 patients 
who were treated during the earlier years of angioplasty in 
the current series. A possible explanation for this is the 
length of the follow-up period. The several reported series 
(19,31,33) had an average follow-up period of 58 months 
compared with 16 months in the current study. The most 
recent results of the series reported by Douglas et al. (32) 
have been presented in an abstract form and only state the 
range of follow-up of 1 to 8 years, making any further time 
comparison difficult. 
An udditionulfktor to explain our high recurrence rates 
may he the age oj’the graft at the time of the ungioplasty 
procedure. An earlier report by Douglas et al. (14) reported 
an excellent restenosis rate of only 12% at the distal anasto- 
mosis during an average follow-up period of 10 months. Of 
interest, 74% of those patients had their angioplasty per- 
formed within 1 year of bypass surgery. By comparison, the 
angiographic recurrence rate in our series for all patients 
who had dilation of a distal anastomotic lesion was 50%. but 
for the Group 1 patients, the recurrence rate was 33%. 
Taking data from both studies, it is clear that the best use of 
angioplasty in vein graft stenosis is in the patient recently 
operated on with a distal anastomotic site stenosis. 
Our series also failed to show any difference in restenosis 
rates when proximal. body and distal graft sites were com- 
pared. This is in agreement with the series by Cote et al. (19). 
However, other studies (15,17,31,32) showed significantly 
lower rates of recurrence in the distal anastomotic sites. 
Conclusions. Although saphenous vein graft angioplasty 
can be carried out with a primary success rate of 92%, on the 
basis of our findings, there is a 6% likelihood of myocardial 
infarction, a 2% likelihood of emergent coronary bypass 
surgery and a 2% mortality rate. However, all of these 
events occurred after angioplasty on grafts implanted >36 
months after operation, resulting in a complication rate of 
14.9% in this group. Additionally, the recurrence rate for 
these older grafts was 64% compared with 33% for grafts 
implanted ~36 months after operation. 
In light of these high complication and recurrence rates, 
all therapeutic options should be carefully considered for the 
patient with late vein graft failure. These could include 
continued medical therapy for the mildly symptomatic pa- 
tient, angioplasty of the native coronary circulation where 
possible or repeat coronary bypass surgery. 
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